CD4 and neoplasm: Results showed an increased number of anti-tumoral immune cells such as CD8+ (with a reduced CD4+/CD8+ ratio), NK and DCs, and a reduced number of pro-tumoral immune cells such as Treg and MDSC (Fig. 2A–H), in tumor masses of SR59230A-, αPD-L1- and SR59203A + αPD-L1-treated mice compared to vehicle condition.